Singapore, Nov. 7 -- Australia based SpeeDx Pty. Ltd. and UK headquartered QuantuMDx Group Ltd. have announced a collaboration with the Foundation for Innovative New Diagnostics (FIND). The global non-profit organization drives development and delivery of diagnostics to combat major diseases affecting the world's poorest populations.

The collaborative project will assess the feasibility of developing low-cost point of care (POC) tests for common sexually transmitted infections (STIs). SpeeDx will use their proprietary PlexPCR(R) technology todevelop multiplex tests for common STIs, including gonorrhoea and Mycoplasma genitalium (Mgen), to be run on the QuantuMDx Q-POCTM POC device.

The QuantuMDx Q-POCTM is a battery-operated, microfluid...